The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells.
Open accessAbstract
Vascular remodeling is central to the pathophysiology of hypertension and atherosclerosis. Recent evidence suggests that vasoconstrictive substances, such as angiotensin II (AII), may function as a vascular smooth muscle growth promoting substance. To explore the role of the counterregulatory hormone, atrial natriuretic polypeptide (ANP) in this process, we examined the effect of ANP (alpha-rat ANP [1-28]) on the growth characteristics of cultured rat aortic smooth muscle (RASM) cells. ANP (10(-7) M) significantly suppressed the proliferative effect of 1% and 5% serum as measured by 3H-thymidine incorporation and cell number, confirming ANP as an antimitogenic factor. In quiescent RASM cells, ANP (10(-7), 10(-6) M) significantly suppressed the basal incorporations of 3H-uridine and leucine by 50 and 30%, respectively. ANP (10(-7), 10(-6) M) also suppressed AII-induced RNA and protein syntheses (by 30-40%) with the concomitant reduction of the cell size. Furthermore, ANP also significantly attenuated the increase of 3H-uridine and leucine incorporations caused by transforming growth factor-beta (4 x 10(-11), 4 x 10(-10) M), a potent hypertrophic factor. These results indicate that ANP possesses an antihypertrophic action on vascular smooth muscle cells. Down-regulation of protein kinase C by 24-h treatment with phorbol 12,13-dibutyrate did not inhibit ANP-induced suppression on 3H-uridine incorporation. Based on the observation that ANP was more potent than a ring-deleted analogue of ANP on inhibiting 3H-uridine incorporation, we conclude that the ANP's inhibitory effect is primarily mediated via the activation of a guanylate cyclase-linked ANP receptor(s). Indeed 8-bromo cGMP mimicked the antihypertrophic action of ANP. Accordingly, we speculate that in addition to its vasorelaxant and natriuretic effects, the antihypertrophic action of ANP observed in the present study may serve as an additional compensatory mechanism of ANP in hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Bold, A. J., Borenstein, H. B., Veress, A. T., & Sonnenberg, H. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90370-2 · Cited by 3,148
Garg, U. C., & Hassid, A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114081 · Cited by 2,155
Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)
Kangawa, K., & Matsuo, H. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91077-5 · Cited by 1,149
Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.
Geisterfer, A. A., Peach, M. J., & Owens, G. K. (1988) · Circulation Research · doi:10.1161/01.res.62.4.749 · Cited by 1,065
A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor
Chinkers, M., Garbers, D. L., Chang, M.-S., Lowe, D. G., Chin, H., Goeddel, D. V., & Schulz, S. (1989) · Nature · doi:10.1038/338078a0 · Cited by 992
Physiological Role of Silent Receptors of Atrial Natriuretic Factor
Maack, T., Suzuki, M., Almeida, F. A., Nussenzveig, D., Scarborough, R. M., McEnroe, G. A., & Lewicki, J. A. (1987) · Science · doi:10.1126/science.2823385 · Cited by 932
The Heart and the Atrial Natriuretic Factor*
CANTIN, M., & GENEST, J. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-2-107 · Cited by 750
Naftilan, A. J., Pratt, R. E., & Dzau, V. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114032 · Cited by 623
Self-citationAngiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.
Berk, B. C., Vekshtein, V, Gordon, H. M., & Tsuda, T. (1989) · Hypertension · doi:10.1161/01.hyp.13.4.305 · Cited by 556
Fuller, F., Porter, J. G., Arfsten, A. E., Miller, J., Schilling, J. W., Scarborough, R. M., Lewicki, J. A., & Schenk, D. B. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76554-5 · Cited by 476
Owens, G. K., Loeb, A., Gordon, D., & Thompson, M. M. (1986) · The Journal of cell biology · doi:10.1083/jcb.102.2.343 · Cited by 412
Angiotensin II Induces c-fos mRNA in Aortic Smooth Muscle
Taubman, M. B., Berk, B. C., Izumo, S., Tsuda, T., Alexander, R. W., & Nadal-Ginard, B. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31290-5 · Cited by 396
Lowe, D. G., Chang, M. S., Hellmiss, R., Chen, E., Singh, S., Garbers, D. L., & Goeddel, D. V. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03518.x · Cited by 370
Owens, G. K., & Schwartz, S. M. (1982) · Circulation Research · doi:10.1161/01.res.51.3.280 · Cited by 310
Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
Campbell-Boswell, M., & Robertson, A. L. (1981) · Experimental and Molecular Pathology · doi:10.1016/0014-4800(81)90066-6 · Cited by 305
Owens, G. K., Geisterfer, A. A., Yang, Y. W., & Komoriya, A. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.2.771 · Cited by 299
Levy, B. I., Michel, J. B., Salzmann, J. L., Azizi, M., Poitevin, P., Safar, M., & Camilleri, J. P. (1988) · Circulation Research · doi:10.1161/01.res.63.1.227 · Cited by 219
Angiotensin II induces c-fos expression in smooth muscle via transcriptional control.
Naftilan, A. J., Pratt, R. E., Eldridge, C. S., Lin, H. L., & Dzau, V. J. (1989) · Hypertension · doi:10.1161/01.hyp.13.6.706 · Cited by 202
Self-citationCaptopril reduces aortic and microvascular growth in hypertensive and normotensive rats.
Wang, D. H., & Prewitt, R. L. (1990) · Hypertension · doi:10.1161/01.hyp.15.1.68 · Cited by 164
Vascular smooth muscle cell hypertrophy and hyperploidy in the Goldblatt hypertensive rat.
Owens, G. K., & Schwartz, S. M. (1983) · Circulation Research · doi:10.1161/01.res.53.4.491 · Cited by 163
Owens, G. K. (1985) · Circulation Research · doi:10.1161/01.res.56.4.525 · Cited by 150
Abell, T. J., Richards, M., Ikram, H., et al. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(89)80158-5 · Cited by 125
Effects of nitroprusside and 8-bromo-cyclic GMP on the contractile activity of the rat aorta.
Lincoln, T. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33437-3 · Cited by 96
Itoh, H., Nakao, K., Mukoyama, M., Yamada, T., Hosoda, K., Shirakami, G., Morii, N., Sugawara, A., Saito, Y., & Shiono, S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114134 · Cited by 58
Self-citationMODULATORY ROLE OF VASOPRESSIN IN SECRETION OF ATRIAL NATRIURETIC POLYPEPTIDE IN CONSCIOUS RATS
Itoh, H., Nakao, K., Yamada, T., Morii, N., Shiono, S., Sugawara, A., Saito, Y., Mukoyama, M., Arai, H., Katsuura, G., et al. (1987) · Endocrinology · doi:10.1210/endo-120-5-2186 · Cited by 36
Self-citation
Cited by
Epstein, F. H., Levin, E. R., Gardner, D. G., & Samson, W. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390507 · Cited by 1,927
The Emerging Concept of Vascular Remodeling
Epstein, F. H., Gibbons, G. H., & Dzau, V. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405193302008 · Cited by 1,575
Self-citationB-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
NITRIC OXIDE SYNTHASE: Role in the Genesis of Vascular Disease
Cooke, M., & Dzau, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.489 · Cited by 710
Nakagawa, O., Ogawa, Y., Itoh, H., Suga, S., Komatsu, Y., Kishimoto, I., Nishino, K., Yoshimasa, T., & Nakao, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118162 · Cited by 617
Self-citation
Metadata
- Authors
- Itoh, H., Pratt, R. E., & Dzau, V. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1990-11-01
- Volume
- 86
- Issue
- 5
- Pages
- 1690-1697
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2154616804
- Cited by
- 326
- References
- 25
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.